Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia

Cancer

Volumn 88, Issue 12, 2000, Pages 2774-2781

  Wang, Beverly Y ^a   Kalir, Tamara ^a   Sabo, Edmond ^b   Sherman, David E ^a   Cohen, Carmel ^a   Burstein, David E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Atypical hyperplasia; Endometrial adenocarcinoma; Endometrial hyperplasia; Endometrium; GLUT1; Human erythrocyte glucose transporter; Immunohistochemistry

Indexed keywords

GLUCOSE TRANSPORTER;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION;

ADENOCARCINOMA; ANIMALS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MONOSACCHARIDE TRANSPORT PROTEINS; PRECANCEROUS CONDITIONS; PROGNOSIS; RABBITS;

EID: 0034660173     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2774::AID-CNCR16>3.0.CO;2-I     Document Type: Article

References (26)

1. Skov BG, Broholm H, Engel U, Franzmann MB, Nielsen AL, Lauritzen AF, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol 1997;16:33-7.
2. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, Diener-West M, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998;22:1012-9.
3. Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima A, Noda K, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynecol Res 1997;23:223-30.
4. Burstein DE, Reder I, Weiser K, Tong T, Pritsker A, Haber R. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod Pathol 1998;11: 392-6.
5. Froehner SC, Davies A, Baldwin SA, Lienhard GE. The blood-nerve barrier is rich in glucose transporter. J Neurocytol 1998;17:173.
6. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol 1992;54:911.
7. Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Localization of erythrocyte/HepG2-type glucose transporter (GLUT1) in human placental villi. Cell Tissue Res 1992;267: 407.
8. Mellanen P, Minn H, Grenman R, Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994;56:622.
9. Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995;153: 798.
10. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 15:2895-8.
11. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51.
12. Younes M, Ertan A, Lechago LV, Somoana J, Lechago J. Human erythryocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiol Biomarkers Prev 1997;6:303-5.
13. Baer SC, Casaubon L, Younes M. Expression of the human erythrocyte glucose transporter GLUT1 in cutaneous neoplasia. J Am Acad Dermatol 1997;37:575-7.
14. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164.
15. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th ed. New York: Springer Verlag, 1994:441.
16. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996;2;1151-4.
17. Juarez D, Lechago LV, Somoano J, Younes M. Glut1 expression in transitional cell carcinoma of the urinary bladder correlates with aggressive biologic behavior [abstract]. Lab Invest 1996;74:75A.
18. Goldfischer M, Weiser K, Pritsker A, Haber R, Burstein D. GLUT1 glucose transporter expression in ovarian neoplasms: a marker of tumor progression |abstract|. Lab Invest 1996;74:90A.
19. Haber RS, Weiser KR, Pritzker A, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 1997;7:363-7.
20. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage 1 nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51.
21. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C. et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998;83(1):34-40.
22. Burstein DE, Hytiroglou P, Miller L, Szporn A, Batheja N, Thung SN. GLUT1 glucose transporter expression in cholangiocarcinoma [abstract]. Mod Pathol 1998;11:151A.
23. Voldstedlund M, Dabelsteen E. Expression of GLUT1 in stratified squamous epithelia and oral carcinoma from humans and rats. APMIS 1997;105:537-45.
24. Pardridge W, Boado R, Farrell C. Brain-type glucose transporter (GLUT1) is selectively localized to the blood-brain-barrier. J Biol Chem 1990;265:18035.
25. Warburg O. On the origin of cancer cells. Science 1956;123: 309.
26. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr., Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595-99.